JPS62270596A - Infection-preventing substance aladapcin - Google Patents
Infection-preventing substance aladapcinInfo
- Publication number
- JPS62270596A JPS62270596A JP61115637A JP11563786A JPS62270596A JP S62270596 A JPS62270596 A JP S62270596A JP 61115637 A JP61115637 A JP 61115637A JP 11563786 A JP11563786 A JP 11563786A JP S62270596 A JPS62270596 A JP S62270596A
- Authority
- JP
- Japan
- Prior art keywords
- water
- alladapsin
- absorption spectrum
- nocardia
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims abstract description 11
- JPUODCQOVNYKMH-UHFFFAOYSA-N 2-[2-[(2,6,7-triamino-7-oxoheptanoyl)amino]propanoylamino]propanoic acid Chemical compound OC(=O)C(C)NC(=O)C(C)NC(=O)C(N)CCCC(N)C(N)=O JPUODCQOVNYKMH-UHFFFAOYSA-N 0.000 title abstract 6
- 108010071906 aladapcin Proteins 0.000 title abstract 3
- 208000015181 infectious disease Diseases 0.000 title description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 241000187654 Nocardia Species 0.000 claims abstract description 5
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 claims abstract description 4
- 241000187681 Nocardia sp. Species 0.000 claims abstract description 4
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 claims abstract description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 3
- 238000000862 absorption spectrum Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000005481 NMR spectroscopy Methods 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims description 3
- YGXVNFMRNNRJJE-UHFFFAOYSA-N [Na].CCCCCCC Chemical compound [Na].CCCCCCC YGXVNFMRNNRJJE-UHFFFAOYSA-N 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 238000004809 thin layer chromatography Methods 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000003623 enhancer Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 241000186361 Actinobacteria <class> Species 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 5
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000013587 production medium Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 244000078127 Eleusine coracana Species 0.000 description 1
- 235000013499 Eleusine coracana subsp coracana Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101150043127 Tonsl gene Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical compound O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000002079 ragi Nutrition 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000020338 yellow tea Nutrition 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Abstract
Description
【発明の詳細な説明】
3、発明の詳細な説明
本発明は新規な感染防御物質アラダプシン(Alada
pcin )およびその製造法に関する。本発明者らは
栃木県塩谷郡で採取した土壌から分離したノカルゾア属
に属する5ANK 60484株がダラム陽性、ダラム
陰性#I菌の感染に対して感染防御効果を有する新規な
感染防御物質を生産することを見出し、これをアラダプ
シン(Aladapcin)と命名した。従って、アラ
ダプシンはこれら細菌に起因するヒト、動物の疾病の予
防または治療に用いられる。アラダプシンを生産する5
ANK60484株の菌学的性状は次の通りである。Detailed Description of the Invention 3. Detailed Description of the Invention The present invention utilizes a novel infection-preventing substance, alladapsin (Aladapsin).
pcin) and its manufacturing method. The present inventors have demonstrated that the 5ANK 60484 strain belonging to the genus Nocalzoa, which was isolated from soil collected in Shioya District, Tochigi Prefecture, produces a novel infection-preventing substance that has an infection-preventing effect against infection by Durham-positive and Durham-negative #I bacteria. This was discovered and was named Aladapsin. Therefore, alladapsin is used for the prevention or treatment of human and animal diseases caused by these bacteria. 5 which produces alladapsin
The mycological properties of ANK60484 strain are as follows.
1)形態学的特徴
1113P[インターナショナル・ストレプトミセス・
プロジェクト(International St、r
eptomycesProject)]規定の培地およ
びワックスマン(S、A。1) Morphological characteristics 1113P [International Streptomyces
Project (International St, r
eptomycesProject)] defined medium and Waxman (S, A.
Waksman)らの勧告しジ・アクチンミセイテス(
’I’l)s Actinomycetes) 、 2
巻〕の培地上で培養する。培養は通常28℃で行う。S
AN’I(60484株の形態学的特徴は気菌糸は生じ
ることなく栄養菌糸は良く伸長しジグザグ(Zig−Z
ag)状とカリ接種培養の数日後には栄養菌糸に明瞭な
分断が観察されることである。分断菌糸は種々の大きさ
の球状ないし洋梨状を示す。その他、特殊器官の形成は
観桜されない。Waksman et al. recommended that the actin mycetes (
'I'l)s Actinomycetes), 2
Culture on the medium of Volume]. Cultivation is usually carried out at 28°C. S
The morphological characteristics of AN'I (strain 60484) are that aerial hyphae do not occur, vegetative hyphae are well elongated, and zigzag (Zig-Z) is observed.
ag) and a few days after potash inoculation culture, clear divisions are observed in the vegetative hyphae. The segmented hyphae exhibit spherical to pear-shaped shapes of various sizes. In addition, the formation of special organs is not observed.
2)各種培養基上の諸性状
各種培養基上で28℃、14日間培養したときの性状は
第1表に示す通りである。色調の表示は日本色彩研究所
版1標準色票”のカラーチップナンバーを表す。2) Properties on various culture media Properties when cultured on various culture media at 28°C for 14 days are as shown in Table 1. The color tone display represents the color chip number of the Japan Color Research Institute version 1 standard color chart.
第 1 表 28℃、14日口の結果を示す。Table 1 The results after 14 days at 28°C are shown.
培 地 名 性 状4−′1°”1
□ うす黄味茶(6−8−8)0“5P2) s
p 産生イず
ア7″ラギ7転 R黄味灰(1−9−10)(ISP
5) sp 産生せずエキス゛鉄寒天 Rう
す黄味茶(6−8−9)(ISP 6) sp
産生せず培地名 性 状
sp 産生ぜず
アスパラギン寒天 Rうす黄味橙(2−9−9)sp
産生ぜず
sp 産生せず
培地名 性 状
水寒天 R黄味法(1−9−10)
sp 産生せず
3)生理学的性質
5ANK 60484株の生理学的性質を第2表に、炭
素源資化性を第3表に示す。Medium Name Properties 4-'1°”1
□ Light yellowish brown (6-8-8) 0"5P2) s
p Production Izua 7″ Ragi 7th R Yellowish gray (1-9-10) (ISP
5) sp Extract without producing iron agar R light yellow tea (6-8-9) (ISP 6) sp
No production medium name Characteristic sp No production asparagine agar R light yellowish orange (2-9-9) sp
No production sp No production Medium name Properties Water agar R yellowing method (1-9-10) sp No production 3) Physiological properties The physiological properties of 5ANK 60484 strain are shown in Table 2, and the carbon source assimilation ability is shown in Table 2. It is shown in Table 3.
第2表 生理学的性質
*培地1: トリジトン・イーストエキスプロス(IS
P 1)培地2:ペプトン・イーストエキス・鉄寒天(
ISI) 6)培地3:チロシン寒天(ISP 7)
4)菌体内成分について
エム・ビー・レシエパリx −(M、P、Lecbev
alier)らの方法〔エイ・ディーラ(A、、Di
s tz )ら著、放線菌の分類(Actj、nomy
cete taxonomy) 、 225頁、198
0年〕に従い、菌体の酸加水分解物のに−パークロマト
グラフイーによる分析を行った結果、メソジアミノピメ
リン酸およびアラビノース、ガラクトースが認められ、
細胞壁型のタイプは■型であることが確認された。また
全菌体糖型はA型であった。さらにエッチ・モルダルス
カ(H・Mordarska)らの方法〔ジャーナル・
オノ・ジェネラル・マイクロバイオロジー(Journ
al ofgeneral Microblology
)、71巻、77頁、1972年〕に従い、菌体内の脂
質を分析した結果、 LCN−A(Lipids ch
aracterj、5tjc of Nocardia
)が存在していた。Table 2 Physiological properties *Medium 1: Trisiton Yeast Expros (IS
P 1) Medium 2: Peptone, yeast extract, iron agar (
ISI) 6) Medium 3: Tyrosine agar (ISP 7) 4) Regarding intracellular components of M.B. Lecbev
Alier et al.'s method [A.
s tz ) et al., Classification of actinomycetes (Actj, nomy
cete taxonomy), p. 225, 198
As a result of perchromatography analysis of the acid hydrolyzate of the bacterial cells, mesodiaminopimelic acid, arabinose, and galactose were found.
The cell wall type was confirmed to be type ■. The glycotype of all bacterial cells was A type. Furthermore, the method of H. Mordarska et al.
Ono General Microbiology (Journ)
al of general Microbology
), vol. 71, p. 77, 1972], the results showed that LCN-A (Lipids ch.
aracterj, 5tjc of Nocardia
) existed.
上記の如き5ANK 60484株の諸性状のうち特に
■菌糸が分断すること、■細胞壁が■型で全菌体中の糖
型がA型であること、■菌体内にLCN−Aが存在する
こと等から、本菌株は、放線菌の中でもノカルジアセア
エ(Nocardl、aceae)科のノカルジア(N
ocar6 j−a)属に属する菌株であることが明ら
かとなシ1.ノカルジア・エスピー(Nocardia
sp、)SANK 60484 (微工研菌寄第742
3号)と命名した。Among the above-mentioned properties of the 5ANK 60484 strain, in particular: 1. Mycelia are fragmented, 2. The cell wall is type 2, and the glycotype in all bacterial cells is type A. 2. LCN-A is present in the bacterial cells. Based on these findings, this bacterial strain is a member of the Nocardia family (Nocardl, aceae) among actinomycetes.
1. It is clear that the strain belongs to the genus ocar6 j-a). Nocardia sp.
sp,) SANK 60484 (Feikoken Bacillus No. 742
No. 3).
以上、アラメゾシンの生産菌について説明したが、放線
菌の諸性質は一定したものではなく、自然的2人工的に
容易に変化することは周知の通りであり、本発明で使用
しうる菌株はノカルジア属に属するアラダプシンを生産
するすべての菌株を包含するものである。The bacteria that produce alamezosin have been explained above, but it is well known that the properties of actinomycetes are not constant and can easily change naturally or artificially. It includes all strains that produce alladapsin belonging to the genus.
本発明における培養は一般放線菌における培養方法に準
じて行われ、液体培地中での振盪培養または通気攪拌培
養によるのが好ましい。培地成分としては、例えば炭素
源としてプPつ糖。Cultivation in the present invention is carried out in accordance with the culture method for general actinomycetes, and is preferably carried out by shaking culture or aerated agitation culture in a liquid medium. As a medium component, for example, P-sugar is used as a carbon source.
マルトース、シュクロース、マンニット、糖蜜。Maltose, sucrose, mannitol, molasses.
グリセリン、デキストリン、澱粉、大豆油、綿実油など
が、窒素源としては大豆粉、落花生粉。Glycerin, dextrin, starch, soybean oil, cottonseed oil, etc. are used as nitrogen sources, and soybean flour and peanut flour are used as nitrogen sources.
綿実粉、ファーマミン、魚粉、コーン・スチープ・リカ
ー、ペゾトン、肉エキス、イースl−。Cottonseed flour, Farmamine, fishmeal, corn steep liquor, pezotone, meat extract, Ease l-.
イースト・エキス、硝酸ナトリウム、硝酸アンモニウム
、硫酸アンモニウム等が、また無機塩として食塩、燐酸
塩、炭酸カルシウム、微景金属塩などが必要に応じて適
宜添加される。液体培養に際してはシリコン油、植物油
、界面活性剤停が消泡剤として適宜使用される。Yeast extract, sodium nitrate, ammonium nitrate, ammonium sulfate, etc., and inorganic salts such as common salt, phosphate, calcium carbonate, micrometal salts, etc. are added as appropriate. For liquid culture, silicone oil, vegetable oil, and surfactant are appropriately used as antifoaming agents.
培地の声は7.0附近、培養温度は24℃から30℃、
特に28℃前後が好ましい。通常80〜96時間の培養
でアラダプシンの生産量は最高値に達する。主として培
養液中の液体部分に存在するアラダプシンは、培養終了
後菌体その他の固型部分を叶いそう土等を濾過助剤とす
る沖過操作、または遠心分離によって除去し、そのろ液
または上清中から抽出・精製される。アラダプシンはそ
の物理化学的性状を利用することにより、例えば吸着剤
を用いて採取することができる。吸着剤としては例えば
活性炭、または吸着用樹脂であるアンバーライ) XA
D−2。The voice of the medium is around 7.0, the culture temperature is 24℃ to 30℃,
Particularly preferred is around 28°C. Usually, the production amount of alladapsin reaches its maximum value after 80 to 96 hours of culture. Alladapsin, which is mainly present in the liquid part of the culture solution, is removed by filtering or centrifugation using soil as a filter aid to remove bacterial cells and other solid parts, and the filtrate or supernatant is removed. Extracted and purified from clear water. Alladapsin can be collected by utilizing its physicochemical properties, for example, using an adsorbent. As an adsorbent, for example, activated carbon or adsorption resin Amberly) XA
D-2.
XAD−4、XA、D−7等(ローム・アンド・ハース
社製)やダイヤイオyl(PIO,HP20.HP5O
゜CHP20P等(三菱化成工業(株)社製)が使用さ
れる。アラダプシンを含む液から上記の如き吸着剤の層
を通過させて含まれる不純物を吸着させて取りのぞくか
、アラダプシンを吸着させた後、メタノール水、アセト
ン水、n−ブタノール水などを用いて溶出する6また、
中性脂溶性物質を培養液から採取する方法、例えば水と
混和しない有機溶媒例えばクロロホルム、酢酸エチル、
n−シタノールなどの単独またはそれらの組み合せによ
り培養テ液または水溶液から不純物を抽出することによ
りアラダプシンを精製することもできる。更にアラダプ
シンを精製するためにはアビセル(旭化成工業(株)社
製)などのセルロース、セファデックスLH−20(フ
ァルマシア社製)などを用いた分配カラムクロマトグラ
フィー、逆相用担体を用いた逆相カラムクロマトグラフ
ィー、アラダプシンと混在する不純物との溶媒に対する
分配率の差を利用した抽出法または向流分配法などが有
効な方法といえる。以上の精製手段を単独′!i−たは
適宜組み合せ、反復用いることによシアラダゾシンを精
製することができる。アラダプシンはまた一般の脂溶性
抗生物質と同じく、培養条件によっては培養液中の菌体
部分に存在する。従ってアルコール類、アセトン等の親
水性有機溶媒によって抽出し、溶媒を除去し、水溶液と
した後、培養ろ液からと同様の方法で抽出精製すること
ができる。XAD-4, XA, D-7, etc. (manufactured by Rohm and Haas)
゜CHP20P (manufactured by Mitsubishi Chemical Industries, Ltd.) is used. The solution containing aladapsin is passed through a layer of adsorbent such as the one described above to adsorb and remove impurities, or after adsorbing aladapsin, it is eluted using methanol water, acetone water, n-butanol water, etc. 6 Also,
Methods for collecting neutral fat-soluble substances from culture solutions, such as organic solvents that are immiscible with water, such as chloroform, ethyl acetate,
Aladapsin can also be purified by extracting impurities from the culture solution or aqueous solution using n-sitanol or the like alone or in combination. To further purify alladapsin, partition column chromatography using cellulose such as Avicel (manufactured by Asahi Kasei Industries, Ltd.), Sephadex LH-20 (manufactured by Pharmacia), etc., and reversed phase using a reversed phase carrier are performed. Effective methods include column chromatography, an extraction method that utilizes the difference in the distribution ratio of aladapsin and mixed impurities to the solvent, or a countercurrent distribution method. Use the above purification methods alone! Sialadazosin can be purified by repeatedly using the above methods or by appropriately combining them. Alladapsin, like general lipid-soluble antibiotics, exists in the bacterial cell portion of the culture medium depending on the culture conditions. Therefore, it is possible to extract with a hydrophilic organic solvent such as alcohol or acetone, remove the solvent, make an aqueous solution, and then extract and purify it in the same manner as from the culture filtrate.
このようにして得られたアラダプシンは次の理化学的性
状を有する。Alladapsin thus obtained has the following physicochemical properties.
(1)物質の性状二両性水溶性、白色粉末。(1) Properties of the substance: Amphoteric, water-soluble, white powder.
(2)分子式:C43H25N5O5
(3)分子量:331
(4)溶解性:
水、メタノールに可溶、アセトン、酢酸エチル、クロロ
ホルムに不溶。(2) Molecular formula: C43H25N5O5 (3) Molecular weight: 331 (4) Solubility: Soluble in water and methanol, insoluble in acetone, ethyl acetate, and chloroform.
(5)呈色反応: ニンヒドリン、ペプチド試薬に陽性。(5) Color reaction: Positive for ninhydrin and peptide reagents.
(6)薄層クロマトグラフイー;
0.42
吸着剤;イーストマン・クロマグラム・シートA132
54展開溶媒;n−ブタノール:水:酢酸(4:1:2
)(7)紫外線吸収スペクトル:
水溶液中で測定した紫外線吸収スペクトルは220nm
以上に特異吸収を示さず、末端吸収のみを示す。(6) Thin layer chromatography; 0.42 Adsorbent; Eastman Chromagram Sheet A132
54 developing solvent; n-butanol:water:acetic acid (4:1:2
) (7) Ultraviolet absorption spectrum: The ultraviolet absorption spectrum measured in an aqueous solution is 220 nm.
No specific absorption is shown above, only terminal absorption is shown.
(8)赤外線吸収スペクトル=νgH、” IKBr法
で測定した赤外線吸収スペクトルは第1図に示す通りで
ある。(8) Infrared absorption spectrum = νgH, "The infrared absorption spectrum measured by the IKBr method is as shown in FIG.
(9)核磁気共鳴吸収スペクトル:δ’ ppm重水中
、外部基準に干MS (テトラメチルシラン)を使用し
て測定した核磁気共鳴吸収スペクトル(270MHz)
は第2図に示す通りである。(9) Nuclear magnetic resonance absorption spectrum: Nuclear magnetic resonance absorption spectrum (270MHz) measured in δ' ppm heavy water using dry MS (tetramethylsilane) as an external standard.
is as shown in FIG.
α1液体クロマトグラフィー:
カラム;マイクロボンダパックCl8(ウォーターズ社
製)溶 媒;5mMヘプタンスルホン酸ナトリウム−1
,5チアセトニトリル
流速;1゜5プ/分
Uv :210nm
保持時間;10.8分
αカ酸加水分解:
6 NHCtで105℃で20時間加水分解した結果、
メソ−ジアミノピメリン酸 1モルおよびD−アラニン
2モルを検出した。α1 liquid chromatography: Column: Microbondapak Cl8 (manufactured by Waters) Solvent: 5mM sodium heptane sulfonate-1
, 5 Thiacetonitrile flow rate: 1°5 p/min Uv: 210 nm Holding time: 10.8 min α-acid hydrolysis: 6 As a result of hydrolysis at 105°C for 20 hours with NHCt,
1 mole of meso-diaminopimelic acid and 2 moles of D-alanine were detected.
0埠感染防御効果 アラダプシンをマウスに24時間前にS、C”。0bori infection prevention effect Alladapsin was administered to mice 24 hours prior to S,C”.
投与後、L coli 5ANK 73175 (2X
10’ cellsAl)を用いて1・V・感染させ
、7日後の生存数を調べた。After administration, L coli 5ANK 73175 (2X
1.V. infection was performed using 10' cells Al), and the number of survivors was examined after 7 days.
以上から、アラダプシンは各種細菌感染性疾患を対照と
する宿主抵抗性増強剤として単独ないし市販の抗菌剤と
併用して使用される。その投与形態としては皮下注射、
静脈内注射、筋肉注射、坐剤などによる非経口投与法あ
るいは錠剤、カプセル剤、散剤、顆粒剤かとによる経口
投与法があげられる。投与量は対象疾患、投与経路およ
び投与回数などによって異なるが、例えば成人に対して
通常は1日10■乃至1gを1回または数回に分けて投
与するのが好ましい。From the above, alladapsin is used alone or in combination with a commercially available antibacterial agent as a host resistance enhancer for various bacterial infectious diseases. Its administration forms include subcutaneous injection,
Parenteral administration methods include intravenous injection, intramuscular injection, and suppositories, and oral administration methods include tablets, capsules, powders, and granules. The dosage varies depending on the target disease, route of administration, frequency of administration, etc., but for adults, it is usually preferable to administer 10 to 1 g per day, either once or in divided doses.
次に実施例をあげて本発明をさらに具体的に説明する。Next, the present invention will be explained in more detail with reference to Examples.
実施例1
ノカルジア・エスピー5ANK 60484株を培地組
成−1で示される培地5O0suを含む21容三角フラ
スコに1白金耳接種し、22Orpmの回転振盪培養機
により28℃で96時間培養し7ヒ。Example 1 One platinum loop of Nocardia sp. 5ANK 60484 strain was inoculated into a 21-volume Erlenmeyer flask containing 500su of the medium shown in medium composition-1, and cultured at 28°C for 96 hours in a rotary shaking incubator at 22 Orpm for 7 h.
この培養液2,51を同一の培地5O1を含1)100
1容タンクに接種し100 rpmの回転により28℃
で48時間通気攪拌培養した。この培養液151を同一
の培地3001を含む6001容タンクに接種し温度2
8℃1通気量0.5 vvm 。This culture solution 2,51 containing the same medium 5O1) 100
Inoculated into a 1-volume tank and heated to 28°C by rotating at 100 rpm.
Culture was carried out with aeration for 48 hours. This culture solution 151 was inoculated into a 6001 volume tank containing the same medium 3001, and the temperature was 2.
8°C/airflow rate 0.5 vvm.
内圧]、、Okg・cJ 、 100 rpmの回転に
よυ91時間通気攪拌培養した。得られた培養液700
1に濾過助剤としてセライト545(米国ジョンズ・マ
ンピル会プロダクト・コーポレーション製)を30kg
加えて炉遇することによシ培養F液6901が得られた
。培養p液をpH5,5に調整しダイヤイオン8に−I
B(H+) (三菱化成工業(株)社製)100A!の
カラムに通しアラダプシンを吸着させた。300Jの脱
イオン水で水洗後、0.5Nアンモニア水4001で溶
出した。得られた溶出液1801を減圧下濃縮し、濃縮
液81が得られた。濃縮液81を−6,5に調整しア7
バー 5 イ) C!G−5O(H+) (ローム・
アンド・ハース社:t!り47のカラムに吸着させた。Internal pressure], Okg·cJ, rotation at 100 rpm for 91 hours with aeration and agitation. Obtained culture solution 700
1, add 30 kg of Celite 545 (manufactured by Johns Mampil Products Corporation, USA) as a filter aid.
In addition, culture F solution 6901 was obtained by heating. Adjust the culture p solution to pH 5.5 and add it to Diaion 8-I
B (H+) (manufactured by Mitsubishi Chemical Industries, Ltd.) 100A! column to adsorb alladapsin. After washing with 300 J of deionized water, it was eluted with 0.5N ammonia water 4001. The obtained eluate 1801 was concentrated under reduced pressure to obtain a concentrated solution 81. Adjust concentrate 81 to -6.5 and a7
Bar 5 a) C! G-5O(H+) (ROHM・
& Haas: t! It was adsorbed onto a 47 column.
251の脱イオン水で洗浄後0.0!5N塩酸水で溶出
した。After washing with 251 deionized water, it was eluted with 0.0!5N hydrochloric acid water.
得られた溶出液23/を水酸化ナトリウムで−7,0に
調整し減圧下濃縮し濃縮液21が得られた。得られた濃
縮液21にアビセル(旭化成工業(株)社製)3001
1を加えて凍結乾燥した。The obtained eluate 23/ was adjusted to -7.0 with sodium hydroxide and concentrated under reduced pressure to obtain concentrate 21. Avicel (manufactured by Asahi Kasei Corporation) 3001 was added to the obtained concentrate 21.
1 was added and freeze-dried.
凍結乾燥粉末をあらかじめ80チアセトニトリル−水(
V/V)で充填した41のアビセルカラムに重層し41
の8(lアセトニトリル−水、201の70%アセトニ
トリル−水241の20%アセトニトリル−水で順次溶
出した。70%および20%アセトニトリル−水でIO
A’ずつ分画していくと活性物質は201アセトニトリ
ル−水で溶出したフラクション煮4〜6に溶出された。The freeze-dried powder was pre-mixed with 80% thiacetonitrile-water (
Layered on 41 Avicel columns packed with V/V)
8 (l acetonitrile-water, 201 ml of 70% acetonitrile-water, 241 ml of 20% acetonitrile-water. 70% and 20% acetonitrile-water.
When fractionation was carried out in units of A', the active substance was eluted in fractions 4 to 6, which were eluted with 201 acetonitrile-water.
この分画を集め減圧下濃縮し凍結乾燥を行って粗粉末1
.91が得られた。得られた粗粉末1.92gを再度8
0%アセトニ) IJルー水で充填した25OWLlの
アビセルカラムに吸着させ、各々1.51の70チ、5
O1%および30%アセトニトリル−水で5O01lI
tずつ順次溶出した。These fractions were collected, concentrated under reduced pressure, and freeze-dried to obtain a crude powder of 1
.. 91 was obtained. 1.92 g of the obtained coarse powder was added to 8
0% acetonate) was adsorbed onto a 25OWL Avicel column packed with IJ Roux water, and 1.51% of 70%, 5% of each
O1% and 30% acetonitrile-5O01lI in water
It was eluted sequentially in t increments.
活性物質はフラクションA6〜9に溶出され、この分画
を集め減圧下濃縮し、凍結乾燥を行って粉末354.8
Wが得られた。得られた粉末354.8■をアンバーラ
イトCG−5O(NH4” ) 270 wLlのカラ
ムに吸着させ水で展開し51ずつ分画を行った。The active substance was eluted in fractions A6-9, and these fractions were collected, concentrated under reduced pressure, and freeze-dried to give a powder of 354.8
W was obtained. The obtained powder (354.8 cm) was adsorbed on a column of 270 wLl of Amberlite CG-5O (NH4''), developed with water, and fractionated into 51 fractions.
アラダプシンを含むフラクションA38〜60を集め凍
結乾燥し13.7■の白色粉末が得られた。Fractions A38 to A60 containing alladapsin were collected and lyophilized to obtain 13.7 cm of white powder.
培地組成−1グルコース 5%
大豆粉 0.75
硫酸アンモニウム 05
プロフロ 0.6
Ca Co 3(155
KH2P0401
pl(7,0
実施例2
実施例1と全く同様の方法で調製した部分精製品アラダ
プシン14■を水で調整したトヨパー ルHW−40(
Fine) (東洋曹達工業(力社製)30iノのカ
ラムに吸着させ水で展開溶出した。Medium composition - 1 Glucose 5% Soy flour 0.75 Ammonium sulfate 05 Proflo 0.6 Ca Co 3 (155 KH2P0401 pl (7.0) Toyo Pearl HW-40 adjusted with water (
Fine) (Toyo Soda Kogyo (manufactured by Rikisha)) It was adsorbed on a 30 inch column and developed and eluted with water.
溶出液を3 mlずつ分画するとアラダプシンは薄層ク
ロマト上半−のスポットとしてフラクションA32〜5
2までに溶出された。溶出分画を集め減圧下濃縮し、凍
結乾燥することにより、アラダプシン5.4■が白色粉
末として得られた。When the eluate was fractionated into 3 ml portions, alladapsin was detected as a spot in the upper half of the thin layer chromatogram in fractions A32-5.
It was eluted by 2. The eluted fractions were collected, concentrated under reduced pressure, and lyophilized to obtain 5.4 cm of alladapsin as a white powder.
第1図はアラダプシンの赤外線吸収スペクトルを示し、
第2図は同物質の核磁気共鳴吸収スペクトルを示す。Figure 1 shows the infrared absorption spectrum of aladapsin,
Figure 2 shows the nuclear magnetic resonance absorption spectrum of the same material.
Claims (1)
)分子量:331 (4)溶解性: 水、メタノールに可溶、アセトン、酢酸エ チル、クロロホルムに不溶。 (5)呈色反応: ニンヒドリン、ペプチド試薬に陽性。 (6)薄層クロマトグラフイー; R_f値;0.42 吸着剤;イーストマン・クロマグラム・シートNo.1
3254展開溶媒;n−ブタノール:水:酢酸(4:1
:2)(7)紫外線吸収スペクトル: 水溶液中で測定した紫外線吸収スペクトル は220nm以上に特異吸収を示さず末端吸収のみを示
す。 (8)赤外線吸収スペクトル:ν^K^B^r_m_a
_xcm^−^1KBr法で測定した赤外線吸収スペク
トルは第1図に示す通りである。 (9)核磁気共鳴吸収スペクトル:δ:ppm重水中、
外部基準にTMS(テトラメチルシラン)を使用して測
定した核磁気共鳴吸収 スペクトル(270MHz)は第2図に示す通りである
。 (10)液体クロマトグラフイー: カラム;マイクロボンダパツクC_1_8(ウオーター
ズ社製) 溶媒;5mMヘプタンスルホン酸ナトリウ ム−1.5%アセトニトリル 流速;1.5ml/分 UV;210nm 保持時間:10.8分 (11)酸加水分解: 6NHClで105℃で20時間加水分解した結果、メ
ソ−ジアミノピメリン酸 1モル およびD−アラニン 2モルを検出した。 2、ノカルジア属に属するアラダプシン生産菌を培養し
て、その培養液よりアラダプシンを採取することよりな
るアラダプシンの製造法。 3、ノカルジア属に属するアラダプシン生産菌がノカル
ジア・エスピーSANK 60484株(微工研菌寄第
7423号)である特許請求の範囲第2項記載の製造法
。[Claims] 1. Alladapsin having the following physical and chemical properties. (1) Properties of substance: Amphoteric, water-soluble, white powder. (2) Molecular formula: C_1_3H_2_5N_5O_5(3
) Molecular weight: 331 (4) Solubility: Soluble in water and methanol, insoluble in acetone, ethyl acetate, and chloroform. (5) Color reaction: Positive for ninhydrin and peptide reagents. (6) Thin layer chromatography; R_f value; 0.42 Adsorbent; Eastman Chromagram Sheet No. 1
3254 developing solvent; n-butanol:water:acetic acid (4:1
:2) (7) Ultraviolet absorption spectrum: The ultraviolet absorption spectrum measured in an aqueous solution shows no specific absorption at 220 nm or more, but only terminal absorption. (8) Infrared absorption spectrum: ν^K^B^r_m_a
The infrared absorption spectrum measured by the _xcm^-^1KBr method is as shown in FIG. (9) Nuclear magnetic resonance absorption spectrum: δ: ppm heavy water,
The nuclear magnetic resonance absorption spectrum (270 MHz) measured using TMS (tetramethylsilane) as an external standard is shown in FIG. (10) Liquid chromatography: Column: Micro Bonder Pack C_1_8 (manufactured by Waters) Solvent: 5mM sodium heptane sulfonate-1.5% acetonitrile Flow rate: 1.5ml/min UV: 210nm Retention time: 10.8 minutes ( 11) Acid hydrolysis: As a result of hydrolysis with 6N HCl at 105°C for 20 hours, 1 mol of meso-diaminopimelic acid and 2 mol of D-alanine were detected. 2. A method for producing alladapsin, which comprises culturing alladapsin-producing bacteria belonging to the genus Nocardia and collecting alladapsin from the culture solution. 3. The production method according to claim 2, wherein the alladapsin-producing bacterium belonging to the genus Nocardia is Nocardia sp.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61115637A JPS62270596A (en) | 1986-05-20 | 1986-05-20 | Infection-preventing substance aladapcin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61115637A JPS62270596A (en) | 1986-05-20 | 1986-05-20 | Infection-preventing substance aladapcin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62270596A true JPS62270596A (en) | 1987-11-24 |
Family
ID=14667571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61115637A Pending JPS62270596A (en) | 1986-05-20 | 1986-05-20 | Infection-preventing substance aladapcin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62270596A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4005488A1 (en) * | 1990-02-21 | 1991-08-22 | Wabner Dietrich | METHOD AND DEVICE FOR WATER DETOXIFICATION |
WO2009098016A1 (en) * | 2008-02-08 | 2009-08-13 | Nutrinova Nutrition Specialties & Food Ingredientsgmbh | Oligopeptides for use as taste modulators |
CN104111303A (en) * | 2014-06-19 | 2014-10-22 | 福建省山河药业有限公司 | Identification method of red nocardia cell wall skeleton |
-
1986
- 1986-05-20 JP JP61115637A patent/JPS62270596A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4005488A1 (en) * | 1990-02-21 | 1991-08-22 | Wabner Dietrich | METHOD AND DEVICE FOR WATER DETOXIFICATION |
WO2009098016A1 (en) * | 2008-02-08 | 2009-08-13 | Nutrinova Nutrition Specialties & Food Ingredientsgmbh | Oligopeptides for use as taste modulators |
EP2093234A1 (en) * | 2008-02-08 | 2009-08-26 | Nutrinova Nutrition Specialties & Food Ingredients GmbH | Oligopeptides for use as taste modulators |
CN104111303A (en) * | 2014-06-19 | 2014-10-22 | 福建省山河药业有限公司 | Identification method of red nocardia cell wall skeleton |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6240292A (en) | Antibiotic substance zofimarin | |
JPS61274696A (en) | Antibiotic chloropolysporin b and c | |
JP2863637B2 (en) | Novel amino oligosaccharide derivative and method for producing the same | |
JPS62270596A (en) | Infection-preventing substance aladapcin | |
HU191849B (en) | Process for preparing compounds with pharmaceutical activity and compositions containing such compounds by means of a new chromobacterium violaceum strain | |
JP3166126B2 (en) | New antibiotics and their manufacture | |
JPH1045738A (en) | Antibiotic substance epoxyquinomicin c and d, its production and antirheumatic agent | |
JPH10234396A (en) | Production of new antitumor agent and soyasapogenol b | |
JP2640932B2 (en) | TAN-866, its production method and microorganism | |
JPS6212227B2 (en) | ||
JP2514632B2 (en) | Antibiotic chloropolysporin A | |
KR830002817B1 (en) | Method for preparing biologically active FR-900156 material | |
JPS6115694A (en) | Antibiotic nitracidomycins a and b and their preparation | |
JPS6337098B2 (en) | ||
JPH02288890A (en) | New physiologically active substance of4949 and production thereof | |
JPS6311341B2 (en) | ||
JPS63157992A (en) | Antibiotic substance n-hydroxydihydroabikoviromycin | |
JPH04633B2 (en) | ||
JPH0586959B2 (en) | ||
JPH0586960B2 (en) | ||
JPH01290673A (en) | Novel substance k3543r1, its use and production | |
JPH01108987A (en) | New material nk86-0186 and production thereof | |
JPH0633272B2 (en) | New antibiotic lactoquinomycin B and method for producing the same | |
JPH05271099A (en) | Phospholipase c inhibitor | |
JPH0578355A (en) | B-1015 compound |